Drug recall · March 27, 2019
Valsartan Tablets USP 160 mg recall
Why: CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Valsartan Tablets USP 160 mg, 100 Tablets (10 x 10) per Unit Dose Blisters, Rx Only, Packaged and Distributed by: American Health Packaging, Columbus, Ohio 43217 (Individual Dose NDC:60687-139-11, Carton NDC#: 60687-139-01)
- Lots / codes
Lot 179791, Mar 2020
- Quantity
- 3337 cartons
- Company
- American Health Packaging, Columbus, OH
- Distribution
- Nationwide USA and Puerto Rico
- Initiated
- March 6, 2019 · Voluntary: Firm initiated
- Classified
- March 21, 2019
- Reported
- March 27, 2019
- Ended
- September 9, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Valsartan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.